Cardiac MRI Shows Myocardial Fibrosis Reversal After Stem Cell Transplant in Young Sickle Cell Patients
Serial cardiovascular magnetic resonance imaging in children and young adults with sickle cell disease demonstrated a 3.4% decrease in mean extracellular volume fraction -- a quantitative marker of diffuse myocardial fibrosis -- from baseline to 12 months after haematopoietic cell transplantation. This is among the first evidence that transplant-related haematological cure translates into measurable cardiac tissue remodelling, highlighting imaging-derived biomarkers as tools for monitoring treatment response beyond haematological endpoints.
The original study
Impact of hematopoietic cell transplantation on myocardial fibrosis in young patients with sickle cell disease.
- Authors
- Sharma A, Selukar S, Bi Y, Merlocco A, Morin CE, Goode C, et al.
- Journal
- Blood
- Type
- Clinical Trial, Journal Article, Research Support, N.I.H., Extramural
- PMID
- 38691679
Original abstract
Serial cardiovascular magnetic resonance evaluation of children and young adults with SCD who underwent hematopoietic cell transplantation showed mean ECV, representing diffuse myocardial fibrosis, decreased 3.4% from baseline to 12 months posttransplantation. This trial was registered at www.clinicaltrials.gov as #NCT04362293.